Why the study?
Are high peripheral levels of h-FABP associated with poor prognosis in end-stage heart failure patients with mechanical circulatory support?
Are high peripheral levels of h-FABP associated with poor prognosis in end-stage heart failure patients with mechanical circulatory support?
Answers are grounded in this paper and cite their sources.
High h-FABP levels at 72 hours post-LVAD implantation may serve as an early marker of severe myocardial damage and poor prognosis in end-stage heart failure patients.
AIM: To associate the time-course of h-FABP and N-terminal pro B-type natriuretic peptide (NT-proBNP)after left ventricular assist device (LVAD) implantation to outcome in end-stage heart failure patients. MATERIALS & METHODS: Patients (n = 14, NYHA class III/IV; left ventricular ejection fraction <25% were enrolled; ten survived up to 1 month after LVAD (survivors) and four died of multiorgan failure within 2 weeks (nonsurvivors). Blood samples were obtained at admission; at 4, 24 and 72 h; and at 1 and 4 weeks after LVAD. RESULTS: h-FABP significantly increases after surgery, decreasing since 72 h in all patients. At 72 h all survivor patients present h-FABP lower than the median value. N-terminal pro B-type natriuretic peptide is not associated with patient outcome at any time. CONCLUSION: High h-FABP levels, indicating the presence of more severe myocardial damage, are associated with a poor prognosis in patients with LVAD, suggesting that an early cardiac injury marker could improve the prediction of clinical outcome.
No takes yet. Share an insight, caveat, or question.
Cabiati et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: